Show simple item record

dc.contributor.authorWard, DG
dc.contributor.authorGordon, NS
dc.contributor.authorBoucher, RH
dc.contributor.authorPirrie, SJ
dc.contributor.authorBaxter, L
dc.contributor.authorOtt, S
dc.contributor.authorSilcock, L
dc.contributor.authorWhalley, CM
dc.contributor.authorStockton, JD
dc.contributor.authorBeggs, AD
dc.contributor.authorGriffiths, M
dc.contributor.authorAbbotts, B
dc.contributor.authorIjakipour, H
dc.contributor.authorLatheef, FN
dc.contributor.authorRobinson, RA
dc.contributor.authorWhite, AJ
dc.contributor.authorJames, ND
dc.contributor.authorZeegers, MP
dc.contributor.authorCheng, KK
dc.contributor.authorBryan, RT
dc.date.accessioned2020-03-26T09:24:19Z
dc.date.issued2019-09
dc.identifier.citationBJU international, 2019, 124 (3), pp. 532 - 544
dc.identifier.issn1464-4096
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3553
dc.identifier.eissn1464-410X
dc.identifier.doi10.1111/bju.14808
dc.description.abstractObjectives To develop a focused panel of somatic mutations (SMs) present in the majority of urothelial bladder cancers (UBCs), to investigate the diagnostic and prognostic utility of this panel, and to compare the identification of SMs in urinary cell-pellet (cp)DNA and cell-free (cf)DNA as part of the development of a non-invasive clinical assay.Patients and methods A panel of SMs was validated by targeted deep-sequencing of tumour DNA from 956 patients with UBC. In addition, amplicon and capture-based targeted sequencing measured mutant allele frequencies (MAFs) of SMs in 314 urine cpDNAs and 153 urine cfDNAs. The association of SMs with grade, stage, and clinical outcomes was investigated by univariate and multivariate Cox models. Concordance between SMs detected in tumour tissue and cpDNA and cfDNA was assessed.Results The panel comprised SMs in 23 genes: TERT (promoter), FGFR3, PIK3CA, TP53, ERCC2, RHOB, ERBB2, HRAS, RXRA, ELF3, CDKN1A, KRAS, KDM6A, AKT1, FBXW7, ERBB3, SF3B1, CTNNB1, BRAF, C3orf70, CREBBP, CDKN2A, and NRAS; 93.5-98.3% of UBCs of all grades and stages harboured ≥1 SM (mean: 2.5 SMs/tumour). RAS mutations were associated with better overall survival (P = 0.04). Mutations in RXRA, RHOB and TERT (promoter) were associated with shorter time to recurrence (P < 0.05). MAFs in urinary cfDNA and cpDNA were highly correlated; using a capture-based approach, >94% of tumour SMs were detected in both cpDNA and cfDNA.Conclusions SMs are reliably detected in urinary cpDNA and cfDNA. The technical capability to identify very low MAFs is essential to reliably detect UBC, regardless of the use of cpDNA or cfDNA. This 23-gene panel shows promise for the non-invasive diagnosis and risk stratification of UBC.
dc.formatPrint-Electronic
dc.format.extent532 - 544
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectHumans
dc.subjectDNA, Neoplasm
dc.subjectPrognosis
dc.subjectRisk Assessment
dc.subjectSequence Analysis, DNA
dc.subjectMutation
dc.subjectDatabases, Genetic
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectMiddle Aged
dc.subjectFemale
dc.subjectMale
dc.subjectUrinary Bladder Neoplasms
dc.subjectHigh-Throughput Nucleotide Sequencing
dc.titleTargeted deep sequencing of urothelial bladder cancers and associated urinary DNA: a 23-gene panel with utility for non-invasive diagnosis and risk stratification.
dc.typeJournal Article
rioxxterms.versionofrecord10.1111/bju.14808
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2019-09
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfBJU international
pubs.issue3
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Prostate and Bladder Cancer Research
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Prostate and Bladder Cancer Research
pubs.publication-statusPublished
pubs.volume124
pubs.embargo.termsNot known
icr.researchteamProstate and Bladder Cancer Researchen_US
dc.contributor.icrauthorJames, Nicholasen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0